首页> 外文OA文献 >PCN8 Axitinib (AXI) and Best Supportive Care (BSC) in the Treatment of Sunitinib-Refractory Patients With Metastatic Renal Cell Carcinoma (mRCC): Results of a Simulated Treatment Comparison (STC) Analyses

【2h】

PCN8 Axitinib (AXI) and Best Supportive Care (BSC) in the Treatment of Sunitinib-Refractory Patients With Metastatic Renal Cell Carcinoma (mRCC): Results of a Simulated Treatment Comparison (STC) Analyses

机译：PCN8阿昔替尼（AXI）和最佳支持治疗（BSC）治疗舒尼替尼难治性转移性肾细胞癌（mRCC）的患者：模拟治疗比较（STC）分析的结果

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
相似文献
相关主题

著录项

作者
Proskorovsky I.; Benedict A.; Larkin J.M.G.; Sandin R.; Chen C.;
展开▼
作者单位

展开▼
年度 2012
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. 索拉非尼与舒尼替尼一线治疗中国转移性肾细胞癌患者的疗效、安全性和生活质量的比较 [J] . Wen Cai, Wen Kong, Baijun Dong, 癌症（英文版） . 2018,第003期
2. Axitinib and Cabozantinib in the Treatment of Sunitinib-Refractory Patients With Metastatic Renal Cell Carcinoma: Results of Matching Adjusted Indirect Treatment Comparison Analysis of the AXIS and METEOR Trials [J] . Robert A. Figlin Clinical advances in hematology & oncology: H&O . 2018,第1Suppla1期

机译：Axitinib和Cabozantinib在治疗Sunitinib-Remartory患者的转移性肾细胞癌：匹配调整后的间接治疗比较分析轴和流星试验的结果
3. Axitinib for the treatment of patients with advanced metastatic renal cell carcinoma (mRCC) after failure of prior systemic treatment [J] . Viktor Grünwald, Axel S Merseburger OncoTargets and therapy . 2012,第6期

机译：阿昔替尼用于先前全身性治疗失败后的晚期转移性肾细胞癌（mRCC）患者的治疗
4. Axitinib, cabozantinib, or everolimus in the treatment of prior sunitinib-treated patients with metastatic renal cell carcinoma: results of matching-adjusted indirect comparison analyses [J] . Irina Proskorovsky, Agnes Benedict, Sylvie Negrier, BMC Cancer . 2018,第1期

机译：Axitinib，Cabozantinib或everolimus治疗先前的Sunitinib治疗的转移性肾细胞癌患者：匹配调整后的间接比较分析结果
5. Integration of Surgery and Systemic Therapy in the Treatment of Locally Advanced and Metastatic Renal Cell Carcinoma [C] . Christopher G. Wood Genitourinary Cancers Symposium . 2011

机译：外科和全身治疗在局部晚期和转移性肾细胞癌中的整合
6. Methodological Approaches for Conducting Claims-Based Studies in Patients Diagnosed with Metastatic Renal Cell Carcinoma [D] . Chun, Danielle S. 2021

机译：用于诊断转移性肾细胞癌的患者的基于权利要求的基于权利要求的方法论方法
7. Axitinib for the treatment of patients with advanced metastatic renal cell carcinoma (mRCC) after failure of prior systemic treatment [O] . Viktor Grünwald, Axel S Merseburger 2012

机译：阿昔替尼用于先前全身性治疗失败后的晚期转移性肾细胞癌（mRCC）患者的治疗
8. Evaluation of The Clinical Effectiveness of Axitinib, Cabozantinib, Everolimus, Nivolumab, Sunitinib And Best Supportive Care (BSC) In Previously Treated Advanced or Metastatic Renal Cell Carcinoma (AMRCC): A Systematic Review And Mixed-Treatment Comparision (MTC) [O] . SJ Edwards, V Wakefield, P Cain, 2017

机译：评估Axitinib，Cabozantib，Everolimus，Nivolumab，Sunitinib和最佳支持性护理（BSC）在先前治疗的晚期或转移性肾细胞癌（AMRCC）的临床疗效评估：系统审查和混合治疗比较（MTC）

PCN8 Axitinib (AXI) and Best Supportive Care (BSC) in the Treatment of Sunitinib-Refractory Patients With Metastatic Renal Cell Carcinoma (mRCC): Results of a Simulated Treatment Comparison (STC) Analyses

著录项

相似文献

相关主题

期刊订阅